Comparative Cytokine Release Profiling Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides a Comparative Cytokine Release Profiling Service to support accurate safety and potency evaluation in cell therapy development. This service addresses challenges such as inconsistent immune activation data, difficulty in comparing CAR construct performance, and uncertainty surrounding cytokine-related safety risks during preclinical studies. Through advanced multiplex immunoassays, standardized co-culture systems, and quantitative cytokine analysis platforms, Creative Biolabs enables reliable cytokine response profiling and comprehensive assessment of immune effector functionality, facilitating informed candidate selection and optimized immunotherapy development.

Introduction

Cytokine release profiling has become an important analytical strategy for evaluating immune activation and inflammatory potential in engineered cell therapies. Activated immune cells produce distinct cytokine patterns, including interferons, interleukins, and chemokines, which reflect functional potency and immune regulation. Comparative profiling of these cytokine signatures enables researchers to differentiate immune responses among cell products, assess safety risks associated with excessive inflammatory signaling, and guide optimization of cell therapy constructs during preclinical development.

Fig.1 Mechanisms Involved in the Induction and Regulation of Cytokine Release Syndrome. (OA Literature) Fig.1 The Underlying Mechanisms Involved in Cytokine Release Syndrome.¹

Service

Creative Biolabs offers a comprehensive solution for sponsors developing CAR-T, TCR-T, or multispecific antibodies who must quantify inflammatory potential before human injection. Our service provides a head-to-head comparison of your lead candidates against negative controls and reference compounds known to induce varying levels of cytokine release. We don't just provide raw data; we provide a biological context that identifies potential vicious cycles of macrophage activation and systemic inflammation.

Our key project support includes quantitative cytokine response analysis, which measures multiple cytokine secretions after antigen stimulation to assess immune activation and engineered cell function. It enables comparative evaluation of CAR constructs and costimulatory domains, supports preclinical safety assessment by profiling inflammatory cytokines, and provides multiparametric immune profiling to reveal immune signaling dynamics for cell therapy development.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs integrates multiple analytical technologies to support comprehensive cytokine profiling and comparative immune response analysis.

Multiplex Cytokine Detection Platforms	Immune Cell Functional Co-Culture Systems
Multiplex Cytokine Detection Platforms enable high-throughput, simultaneous quantification of multiple cytokines in one sample, sensitively detecting inflammatory and regulatory immune mediators.	Immune Cell Functional Co‑culture Systems assess engineered immune cell cytokine responses against antigen‑positive target cells under standardized, reproducible conditions.
Quantitative Immunoassay Technologies	High-Content Data Analysis
Quantitative Immunoassay Technologies enable accurate, wide‑range cytokine measurement to detect early and robust immune activation.	High‑Content Data Analysis uses bioinformatics to visualize and compare immune activation profiles across constructs, donors, and experimental groups.

Our Workflow

To initiate the service, clients typically provide required starting materials, including purified antibodies, viral vectors, or engineered T‑cells, reference benchmarks for comparison, and target specifications such as specific cell lines or donor requirements.

Workflow of Comparative Cytokine Release Profiling. (Creative Biolabs Original)

Final deliverables include a comprehensive safety report, comparative benchmark analysis against approved references, and statistical validation data with P-values and EC50 / IC50 curves.

Core Benefits

Customized Assay Architectures: Design and execution of head-to-head comparisons between proprietary TRuC-T, CAR-T, or bispecific antibody formats and established clinical standards.
Deep Mechanistic Insights: Quantitative profiling of the "vicious cycle" involving tumor pyroptosis and subsequent macrophage activation.
Head-to-Head Benchmarking: Precise evaluation of candidate performance against approved second-generation CAR benchmarks to quantify reductions in IL-6, TNF-alpha, and IFN-gamma.
Advanced Kinetic Signaling Analysis: High-sensitivity detection of early signaling events to distinguish physiological activation from toxic over-activation.

FAQs

Q: How does this service differentiate between normal T-cell activation and CRS-inducing events?

A: We monitor the decoupling of lytic factors (perforin/granzyme) from inflammatory cytokines. This allows us to identify candidates that maintain high cytotoxicity while minimizing the systemic "vicious cycle" that leads to CRS.

Q: Can you perform comparative profiling for solid tumor targets?

A: Yes. We have optimized co-culture systems for solid tumor markers, ensuring that the profiling accounts for the unique immunosuppressive environments of solid malignancies.

Q: What is the benefit of using TRuC-T cells as a benchmark in my study?

A: TRuC-T cells engage the entire TCR complex, providing a more physiological response with lower cytokine release compared to second-generation CARs. Using them as a benchmark helps you set a "gold standard" for safety in your pipeline.

Q: Do you offer specific markers for neurotoxicity (ICANS) prediction?

A: Beyond systemic cytokines, we can measure markers associated with BBB disruption and vascular endothelium activation to provide a more comprehensive ICANS risk profile.

Partner with Us

Creative Biolabs provides a high-resolution window into the safety profile of your therapeutic candidates. By leveraging our Comparative Cytokine Release Profiling Service, you can ensure that your immunotherapy project is built on a foundation of rigorous, benchmarked safety data, effectively mitigating the risks of CRS and ICANS before they reach the clinic. Ready to discuss your project? Our team of immunology specialists is standing by to help you design the perfect safety assessment strategy. Contact Our Team for More Information and to Discuss Your Project.

Reference

Xiao, Xinyi et al. "Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies." Journal of experimental & clinical cancer research: CR vol. 40,1 367. 18 Nov. 2021. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s13046-021-02148-6

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.